Hot Life Science Investor Mandate 2: Big Pharmaceutical Looks for Biomarker-Based Oncology Therapeutic Assets

15 Oct

A big pharmaceutical corporation based in Western Europe with offices worldwide forms partnerships with early-stage biotech companies. The firm also invests via a venture arm, which is highly strategic in nature; the firm shares access to opportunities with the fund. The firm invests in technologies from an early discovery stage onwards, and partners with companies worldwide.

The firm’s therapeutic areas are Oncology & Cancer Immunotherapy, Ophthalmology, Immunology, Infectious Disease & Specialty Care, and Neuroscience. In the oncology sector, the firm seeks assets that have a biomarker hypothesis that can be used to select and stratify patient populations; in addition to therapeutic assets, biomarker diagnostics are also of interest. In Ophthalmology, the firm focuses on ‘back of the eye’ diseases such as AMD, diabetic retinopathy, and diabetic macular edema, and is also interested in other eye diseases such as retinitis of prematurity, retinitis pigmentosa, uveitis, dry eye, and glaucoma. In immunology/infectious disease, the firm focuses on hepatitis B, influenza and antibacterials; the firm is also interested in respiratory infections, HPV and HIV. In neurology, the firm focuses on neurodegenerative diseases (Alzheimer’s, Parkinson’s), schizophrenia, multiple sclerosis, depression, and autism spectrum disorders. Opportunities from the lead op stage onwards are evaluated by the firm’s therapeutic area groups.

The firm is interested in companies that align with the firm’s areas of focus and which have attained proof of principle or proof of concept data for their asset, and prefers that assets have obtained robust preclinical data across several species. Evidence of target engagement is of importance. In oncology assets, the possibility of combinability with the firm’s asset is also of interest.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: